A Hernia, a Wedding, and Nine Days: Timing Avatrombopag Against a Transplant List
A cirrhotic patient awaiting liver transplant needs hernia repair before it strangulates — but the drug that would spare him a platelet transfusion, and the alloimmunization risk that comes with one, needs more runway than his calendar wants to give it.
M.O., a 58-year-old man, has spent the four months since he joined the liver transplant waiting list learning to move at a slower pace than thirty years of long-haul trucking ever asked of him. His cirrhosis, from longstanding metabolic-dysfunction-associated steatotic liver disease, is the reason for that list, and his MELD of 14 places his waitlist mortality on a scale of months rather than years — close enough that an intercurrent complication knocking him temporarily off the active list would cost him something real. An umbilical hernia he'd been ignoring for over a year has become tender and occasionally difficult to reduce over the past two weeks, and his surgeon wants it repaired before it strangulates rather than after. His platelet count, 32,000/µL, reflects splenic sequestration from portal hypertension rather than any active bleeding process, and the surgical threshold for his repair is 50,000/µL — a gap large enough that something has to raise it before anyone operates.
The complicating detail is his transplant candidacy. Avatrombopag can close that gap without a transfusion — ADAPT-1 and ADAPT-2, the pivotal trials behind it, enrolled cirrhotic patients before scheduled procedures up to a MELD of 24 and split them into a low-baseline cohort under 40,000/µL and a high-baseline cohort from 40,000 up to 50,000/µL; his count of 32,000 places him in the low cohort the trials actually dosed for, and his MELD of 14 sits well inside their eligibility ceiling, not near its edge. What the trials don't buy him is speed: it needs roughly ten to thirteen days from the first dose to reach that point, and his daughter's wedding, which he has told the team twice he does not intend to miss, falls nine days out. A platelet transfusion would work immediately, but every unit carries a real chance of HLA alloimmunization, and a transplant candidate who becomes broadly sensitized is a transplant candidate who waits longer, or gets a worse-matched organ, the next time one becomes available. The hernia itself isn't yet strangulated — tender and intermittently difficult to reduce, but still reducible on exam this morning — which is the detail the timeline argument actually turns on.
On the ward, working the calendar backward from the wedding
I'd start avatrombopag today, at the 60-milligram dose for a baseline under 40, and target the repair for day ten to twelve. ADAPT-1 and ADAPT-2 were both run in exactly this population — cirrhotic patients before a scheduled procedure — and reliably got platelet counts above transfusion thresholds without a single platelet product. For a transplant candidate, avoiding any HLA exposure at all is worth a short, planned delay.
I'm less comfortable waiting the full window than that makes it sound. This hernia has gotten harder to reduce over two weeks, not stayed stable — if it strangulates while we're waiting on day-ten pharmacology, we're doing an emergency operation on an unprepared platelet count instead of a planned one on a corrected count, which is strictly worse.
The alloimmunization argument is real, but it's a future risk against a present one — a strangulated bowel doesn't wait for us to finish weighing transplant logistics.
I think you're both right about different risks, and the exam in front of us today is the thing that should actually decide it: it's still reducible. That's not nothing — it's the specific finding that argues against imminent strangulation, not a generic reassurance. I'd start avatrombopag now and re-examine him daily rather than waiting passively for day ten; if reducibility worsens or he develops any sign of incarceration at any point before then, that changes the calculus immediately and we transfuse and operate that day, wedding or not.
But absent that change, a transplant candidate's first blood-product exposure shouldn't be spent on a hernia we had ten days of warning to plan around.
Agreed: avatrombopag started today, repair scheduled for day 11, daily exams in the meantime with an explicit, named trigger (any worsening reducibility or new signs of incarceration) for immediate transfusion and same-day surgery regardless of that schedule.
He proceeds to repair on schedule with no platelet-product exposure at all before his wedding.
The plan converts immediately to transfusion and emergent repair — the surgeon's risk, not the hepatologist's, becomes the operative one that day.